519 related articles for article (PubMed ID: 12067985)
21. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.
Gomez BP; Riggins RB; Shajahan AN; Klimach U; Wang A; Crawford AC; Zhu Y; Zwart A; Wang M; Clarke R
FASEB J; 2007 Dec; 21(14):4013-27. PubMed ID: 17660348
[TBL] [Abstract][Full Text] [Related]
22. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
24. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
[TBL] [Abstract][Full Text] [Related]
25. IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.
Ning Y; Riggins RB; Mulla JE; Chung H; Zwart A; Clarke R
Mol Cancer Ther; 2010 May; 9(5):1274-85. PubMed ID: 20457620
[TBL] [Abstract][Full Text] [Related]
26. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
McClelland RA; Barrow D; Madden TA; Dutkowski CM; Pamment J; Knowlden JM; Gee JM; Nicholson RI
Endocrinology; 2001 Jul; 142(7):2776-88. PubMed ID: 11415996
[TBL] [Abstract][Full Text] [Related]
27. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
28. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells.
Scafoglio C; Ambrosino C; Cicatiello L; Altucci L; Ardovino M; Bontempo P; Medici N; Molinari AM; Nebbioso A; Facchiano A; Calogero RA; Elkon R; Menini N; Ponzone R; Biglia N; Sismondi P; De Bortoli M; Weisz A
J Cell Biochem; 2006 Aug; 98(5):1163-84. PubMed ID: 16514628
[TBL] [Abstract][Full Text] [Related]
29. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
30. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
31. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
[TBL] [Abstract][Full Text] [Related]
32. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
33. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
34. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
Louie MC; McClellan A; Siewit C; Kawabata L
Mol Cancer Res; 2010 Mar; 8(3):343-52. PubMed ID: 20215421
[TBL] [Abstract][Full Text] [Related]
37. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM
Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806
[TBL] [Abstract][Full Text] [Related]
38. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1.
Wang DY; Fulthorpe R; Liss SN; Edwards EA
Mol Endocrinol; 2004 Feb; 18(2):402-11. PubMed ID: 14605097
[TBL] [Abstract][Full Text] [Related]
39. Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.
Sismondi P; Biglia N; Ponzone R; Fuso L; Scafoglio C; Cicatiello L; Ravo M; Weisz A; Cimino D; Altobelli G; Friard O; De Bortoli M
Maturitas; 2007 May; 57(1):50-5. PubMed ID: 17395409
[TBL] [Abstract][Full Text] [Related]
40. A potent specific pure antiestrogen with clinical potential.
Wakeling AE; Dukes M; Bowler J
Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
